EUCTR2020-003277-22-IT进行中（未招募）1 期
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymphoma. A randomized, open label, phase III study by Fondazione Italiana Linfomi. - FIL_FOLL19
FONDAZIONE ITALIANA LINFOMI ONLUS0 个研究点目标入组 602 人开始时间: 2021年10月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 602
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Histologically documented diagnosis of CD20+ Follicular lymphoma grade 1-2 or 3a, according to WHO 2017;
- •2)Age = 18 years;
- •3)ECOG performance status 0-2;
- •4)No previous immunochemotherapy for the lymphoma (localized radiotherapy or rituximab monotherapy with max of 4 doses are allowed);
- •5)Ann Arbor stage II-IV;
- •6)High tumor burden as per GELF criteria;
- •7)At least one site of measurable nodal disease at baseline = 1.5 cm in the longest transverse diameter as determined by CT scan (MRI is allowed if CT scan cannot be performed); or evaluable disease at baseline FDG-PET scan (at least one metabolic active site of disease);
- •8)Adequate hematological counts (unless due to bone marrow involvement by lymphoma);
- •9)Adequate renal function defined as creatinine = 2 mg/dL, unless secondary to lymphoma;
- •10)Adequate hepatic function defined as bilirubin = 2 mg/dL, unless secondary to lymphoma;
- •11)LVEF > 50% at bidimensional echocardiogram (mandatory only for patients receiving R/G-CHOP);
- •12)Life expectancy = 6 months;
- •13)Subject understands and voluntarily signs an informed consent form;
- •14)Subject must be able to adhere to the study visit schedule and other protocol requirements;
- •15)Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active. This applies for the time period between signing of the informed consent form and 12 months after last rituximab dose or 18 months after last obinutuzumab dose.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 301
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 301
排除标准
- •1)Histological diagnosis different from FL grade 1-3a WHO 2017 classification;
- •2)Suspect or clinical evidence of CNS involvement by lymphoma;
- •3)Contraindication to the use of anti-CD20 monoclonal antibodies;
- •4)Subject has received any anticancer therapy (chemotherapy, immunotherapy, investigational therapy, including targeted small molecule agents) within 14 days prior to the first dose of study drug;
- •5)Noteworthy history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent;
- •6)Any history of other active malignancies within 3 years prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uterine; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; limited stage surgically removed breast cancer or adequately treated with radiation therapy; limited stage prostate carcinoma surgically removed or adequately treated with radiation therapy; previous malignancy confined and surgically resected with curative intent;
- •7)Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- •-Uncontrolled and/or active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARS-CoV-2;
- •-Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV- DNA) are eligible. Patients with presence of HCV antibody are eligible only if PCR negative for HCV-RNA;
- •8)Women who are pregnant or breastfeeding.
研究者
相似试验
已完成
不适用
Reduced intensity chemotherapy given with and without imatinib mesylate in patients >/= 60 years considered unfit for standard chemotherapy with previously untreated acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T): a randomized phase II studyAcute myeloid leukemia (AML)LeukemiaCancerISRCTN70542454Dutch Haemato-oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON)60
未知
1 期
Clinical evaluation of NK211 and CDDP for cervical cancer.Advanced and/or recurrent cervical cancer.JPRN-jRCT2080221794ippon Kayaku Co., Ltd.
已完成
1 期
Phase I/II study of combination chemotherapy with Paclitaxel and TS-1 and Cisplatin for unresectable/ recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000004729School of Medicine, Keio University40
招募中
不适用
A study to compare two types of therapy in locally advanced gall bladder cancer: Chemotherapy combined with irreversible electroporation versus chemotherapy aloneCTRI/2021/05/033803SERB
已完成
2 期
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced lung squamous cell carcinomaung cancerJPRN-UMIN000006983Hamamatsu University School of Medicine50